Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) has been identified as one of the leading factors contributing to the rising incidence of advanced liver disease, with its prevalence increasing annually. Currently, the primary treatment strategies focus on lifestyle modifications, including dietary adjustments and physical exercise, with weight loss being particularly crucial. Meanwhile, significant progress has been made in the development of pharmacological treatments, especially thyroid hormone receptor β (THR-β) agonists, which have garnered considerable attention due to their potential efficacy in MASH treatment. This review aims to provide an in-depth exploration of the latest research advancements in THR-β agonists for MASH treatment, offering new therapeutic strategies and perspectives for clinical practice.